MX2017005977A - Anticuerpos biespecificos y metodos de uso en oftalmologia. - Google Patents
Anticuerpos biespecificos y metodos de uso en oftalmologia.Info
- Publication number
- MX2017005977A MX2017005977A MX2017005977A MX2017005977A MX2017005977A MX 2017005977 A MX2017005977 A MX 2017005977A MX 2017005977 A MX2017005977 A MX 2017005977A MX 2017005977 A MX2017005977 A MX 2017005977A MX 2017005977 A MX2017005977 A MX 2017005977A
- Authority
- MX
- Mexico
- Prior art keywords
- bispecific antibodies
- ophthalmology
- methods
- human
- 1beta
- Prior art date
Links
- 102100034608 Angiopoietin-2 Human genes 0.000 abstract 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 abstract 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 abstract 1
- 101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 abstract 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000058223 human VEGFA Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192517 | 2014-11-10 | ||
| PCT/EP2015/075879 WO2016075037A1 (en) | 2014-11-10 | 2015-11-06 | Bispecific antibodies and methods of use in ophthalmology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017005977A true MX2017005977A (es) | 2017-06-29 |
Family
ID=51868112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017005977A MX2017005977A (es) | 2014-11-10 | 2015-11-06 | Anticuerpos biespecificos y metodos de uso en oftalmologia. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10730938B2 (show.php) |
| EP (1) | EP3218399A1 (show.php) |
| JP (1) | JP2017537896A (show.php) |
| KR (1) | KR20170080584A (show.php) |
| CN (1) | CN107074941A (show.php) |
| AR (1) | AR102592A1 (show.php) |
| AU (1) | AU2015345323A1 (show.php) |
| BR (1) | BR112017009764A2 (show.php) |
| CA (1) | CA2963175A1 (show.php) |
| IL (1) | IL251128A0 (show.php) |
| MX (1) | MX2017005977A (show.php) |
| RU (1) | RU2017120360A (show.php) |
| SG (1) | SG11201703428SA (show.php) |
| TW (1) | TW201632551A (show.php) |
| WO (1) | WO2016075037A1 (show.php) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2537100T3 (es) | 2009-04-07 | 2015-06-02 | Roche Glycart Ag | Anticuerpos biespecíficos trivalentes |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| BR112017009790A2 (pt) * | 2014-11-10 | 2017-12-19 | Hoffmann La Roche | anticorpos direcionados ao anti-ang2 e métodos de uso |
| JP2017537896A (ja) | 2014-11-10 | 2017-12-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二重特異性抗体及び眼科に使用する方法 |
| AU2015345322A1 (en) | 2014-11-10 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-PDGF-B antibodies and methods of use |
| EP3218402A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-il-1beta antibodies and methods of use |
| WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
| CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
| KR102543878B1 (ko) * | 2016-08-23 | 2023-06-14 | 메디뮨 리미티드 | 항-ｖｅｇｆ-ａ 및 항-ａｎｇ2 항체 및 이의 용도 |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| CN110818793A (zh) | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| KR20240042566A (ko) * | 2018-12-21 | 2024-04-02 | 에프. 호프만-라 로슈 아게 | Vegf 및 il-1베타에 결합하는 항체 및 이의 사용 방법 |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| CN115397850A (zh) * | 2020-03-30 | 2022-11-25 | 豪夫迈·罗氏有限公司 | 与vegf和pdgf-b结合的抗体及其使用方法 |
| WO2022253314A1 (zh) * | 2021-06-04 | 2022-12-08 | 信达生物制药(苏州)有限公司 | 结合VEGF和Ang2的双特异性结合分子以及其用途 |
| CN116925234B (zh) * | 2022-04-02 | 2024-05-31 | 合肥星眸生物科技有限公司 | 一种编码抗vegf-a和ang-2双特异性抗体的aav载体 |
| CN117467025B (zh) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | 一种抗vegf和补体双功能融合蛋白及其应用 |
| WO2025211874A1 (ko) * | 2024-04-04 | 2025-10-09 | 주식회사 크로스포인트테라퓨틱스 | 인간 항체 fc 변이체 포함 이중항체 및 그 용도 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| AU2003208946A1 (en) | 2002-02-28 | 2003-09-16 | Eli Lilly And Company | Anti-interleukin-1 beta analogs |
| EP1517921B1 (en) | 2002-06-28 | 2006-06-07 | Domantis Limited | Dual specific ligands with increased serum half-life |
| EP1590369B1 (en) | 2003-01-24 | 2016-03-16 | Applied Molecular Evolution, Inc. | Human il-1 beta antagonists |
| CA2514584C (en) | 2003-01-28 | 2012-05-29 | Academisch Ziekenhuis Leiden | Peptide inhibitors of toxins derived from ll-37 |
| WO2005052002A2 (en) | 2003-11-20 | 2005-06-09 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
| US20050282233A1 (en) * | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
| PL1838733T3 (pl) | 2004-12-21 | 2012-02-29 | Medimmune Ltd | Przeciwciała skierowane przeciwko angiopoetynie-2 i ich zastosowania |
| AU2006259664A1 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| AU2008247382B2 (en) | 2007-05-07 | 2014-06-05 | Medimmune, Llc | Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8293714B2 (en) | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| EP2293816B1 (en) | 2008-06-06 | 2012-11-07 | XOMA Technology Ltd. | Methods for the treatment of rheumatoid arthritis |
| RU2368359C1 (ru) | 2008-07-22 | 2009-09-27 | Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) | Способ лечения возрастной макулярной дегенерации |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| BRPI1007371A2 (pt) | 2009-01-29 | 2018-03-27 | Abbott Lab | proteínas de ligação a il-1 |
| CA2775402A1 (en) | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Il-1 binding proteins |
| TW201138821A (en) * | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| SG185473A1 (en) | 2010-05-07 | 2012-12-28 | Xoma Technology Ltd | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS |
| BR112013003279A2 (pt) | 2010-08-13 | 2016-06-14 | Genentech In | “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal” |
| WO2012034039A2 (en) | 2010-09-10 | 2012-03-15 | Apexigen, Inc. | Anti-il-1 beta antibodies and methods of use |
| JP6009455B2 (ja) | 2010-12-21 | 2016-10-19 | アッヴィ・インコーポレイテッド | Ｉｌ−１アルファおよびベータ二重特異的二重可変ドメイン免疫グロブリンおよびその使用 |
| MX348071B (es) | 2011-03-16 | 2017-05-26 | Amgen Inc | Variantes de fc. |
| EP2726088B1 (en) | 2011-06-29 | 2019-01-02 | Amgen Inc. | Predictive biomarker of survival in the treatment of renal cell carcinoma |
| SG11201408196RA (en) * | 2012-06-28 | 2015-03-30 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| EA032192B1 (ru) | 2012-07-13 | 2019-04-30 | Роше Гликарт Аг | Биспецифическое антитело к vegf/ang-2, нуклеиновая кислота, кодирующая это антитело, вектор, содержащий нуклеиновую кислоту, клетка-хозяин, способ получения биспецифического антитела и содержащая его фармацевтическая композиция |
| WO2014049100A1 (en) | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents |
| BR112015006363A2 (pt) | 2012-09-28 | 2017-08-08 | Boehringer Ingelheim Int | combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r |
| SG11201503637SA (en) | 2012-11-08 | 2015-06-29 | Clearside Biomedical Inc | Methods and devices for the treatment of ocular diseases in human subjects |
| HK1216428A1 (zh) * | 2012-11-09 | 2016-11-11 | 辉瑞公司 | 血小板衍生生长因子b之特异性抗体及其组合物和用途 |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| US9062108B2 (en) | 2013-03-15 | 2015-06-23 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 and/or IL-17 |
| TWI747803B (zh) * | 2013-04-29 | 2021-12-01 | 瑞士商赫孚孟拉羅股份公司 | 人類結合ｆｃｒｎ之經修飾抗體及使用方法 |
| CA2923591A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Combination therapy with an anti-ang2 antibody and a cd40 agonist |
| MX382848B (es) | 2014-01-15 | 2025-03-13 | Hoffmann La Roche | Variantes de región fc con propiedades de unión a receptor fc neonatal (fcrn) modificadas y de unión a proteína a mantenidas. |
| UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| AU2015345322A1 (en) | 2014-11-10 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-PDGF-B antibodies and methods of use |
| JP2017537896A (ja) | 2014-11-10 | 2017-12-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二重特異性抗体及び眼科に使用する方法 |
| EP3218402A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-il-1beta antibodies and methods of use |
| BR112017009790A2 (pt) | 2014-11-10 | 2017-12-19 | Hoffmann La Roche | anticorpos direcionados ao anti-ang2 e métodos de uso |
| WO2016209972A1 (en) | 2015-06-26 | 2016-12-29 | Amgen Inc. | Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor |
| MX2019014199A (es) | 2017-06-02 | 2020-01-23 | Boehringer Ingelheim Int | Tratamiento de combinacion antineoplasico. |
-
2015
- 2015-11-06 JP JP2017525022A patent/JP2017537896A/ja active Pending
- 2015-11-06 KR KR1020177011694A patent/KR20170080584A/ko not_active Withdrawn
- 2015-11-06 MX MX2017005977A patent/MX2017005977A/es unknown
- 2015-11-06 SG SG11201703428SA patent/SG11201703428SA/en unknown
- 2015-11-06 RU RU2017120360A patent/RU2017120360A/ru not_active Application Discontinuation
- 2015-11-06 EP EP15790946.6A patent/EP3218399A1/en not_active Withdrawn
- 2015-11-06 BR BR112017009764A patent/BR112017009764A2/pt not_active Application Discontinuation
- 2015-11-06 CN CN201580060833.XA patent/CN107074941A/zh active Pending
- 2015-11-06 AU AU2015345323A patent/AU2015345323A1/en not_active Abandoned
- 2015-11-06 WO PCT/EP2015/075879 patent/WO2016075037A1/en not_active Ceased
- 2015-11-06 CA CA2963175A patent/CA2963175A1/en not_active Abandoned
- 2015-11-09 TW TW104136909A patent/TW201632551A/zh unknown
- 2015-11-09 AR ARP150103645A patent/AR102592A1/es unknown
-
2017
- 2017-03-13 IL IL251128A patent/IL251128A0/en unknown
- 2017-05-09 US US15/590,176 patent/US10730938B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016075037A1 (en) | 2016-05-19 |
| AR102592A1 (es) | 2017-03-08 |
| SG11201703428SA (en) | 2017-05-30 |
| KR20170080584A (ko) | 2017-07-10 |
| BR112017009764A2 (pt) | 2018-02-20 |
| AU2015345323A1 (en) | 2017-04-06 |
| RU2017120360A (ru) | 2018-12-13 |
| EP3218399A1 (en) | 2017-09-20 |
| JP2017537896A (ja) | 2017-12-21 |
| RU2017120360A3 (show.php) | 2019-10-18 |
| US20170240629A1 (en) | 2017-08-24 |
| TW201632551A (zh) | 2016-09-16 |
| IL251128A0 (en) | 2017-04-30 |
| CA2963175A1 (en) | 2016-05-19 |
| US10730938B2 (en) | 2020-08-04 |
| CN107074941A (zh) | 2017-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017005977A (es) | Anticuerpos biespecificos y metodos de uso en oftalmologia. | |
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| PH12016501644A1 (en) | Binding proteins and methods of use thereof | |
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| EA201891186A1 (ru) | Антитела, нейтрализующие вирус иммунодефицита человека | |
| MX2021014735A (es) | Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos. | |
| PH12017501521A1 (en) | Anti-dll3 chimeric antigen receptors and methods of use | |
| EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
| NZ733055A (en) | Anti-c10orf54 antibodies and uses thereof | |
| PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
| PH12017500825A1 (en) | Anti-cldn chimeric antigen receptors and methods of use | |
| MX2017007491A (es) | Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso. | |
| MX421186B (es) | Constructos de anticuerpos. | |
| MX2017005325A (es) | Enfoque de inmunoterapias de combinación para el tratamiento del cancer. | |
| MX2016010953A (es) | Proteinas de fc multimericas. | |
| PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
| MX2017005975A (es) | Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso. | |
| MX2023006416A (es) | Anticuerpos, usos y metodos. | |
| MX2019005299A (es) | Anticuerpos anti-receptor del factor de crecimiento de tipo insulinico humano 1 (anti-igf-1r) con abolicion de la union al fcrn y su uso en el tratamiento de enfermedades oculares vasculares. | |
| MX2016004802A (es) | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. | |
| WO2015153997A3 (en) | Notch3 antibodies and uses thereof | |
| EA201692395A1 (ru) | Новые соединения | |
| PH12017500018B1 (en) | Myo-inositol and probiotics, and their use | |
| MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. | |
| EA201790790A1 (ru) | Антитела человека против vegfr-2/kdr |